EASL Recommendations on Treatment of Hepatitis C 2018.

[1]  J. Dufour,et al.  Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. , 2018, Journal of hepatology.

[2]  N. Terrault,et al.  Direct‐acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local‐regional therapy or liver transplant waitlist dropout , 2018, Hepatology.

[3]  R. Chung,et al.  The short‐term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct‐acting antivirals: An ERCHIVES study , 2018, Hepatology.

[4]  P1-063: Effectiveness of elbasvir/grazoprevir in patients with chronic hepatitis C and chronic kidney disease: results from the veterans affairs system , 2018, Journal of Viral Hepatitis.

[5]  J. Blackard,et al.  Hepatitis C transmission from seropositive, nonviremic donors to non–hepatitis C liver transplant recipients , 2018, Hepatology.

[6]  S. Mauss,et al.  Direct‐acting antiviral treatment of chronic HCV‐infected patients on opioid substitution therapy: Still a concern in clinical practice? , 2018, Addiction.

[7]  B. Leggett,et al.  Long-term follow-up of patients with chronic HCV infection and compensated or decompensated cirrhosis following treatment with sofosbuvir-based regimens , 2018 .

[8]  J. Rockstroh,et al.  Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  R. Facchetti,et al.  The optimal timing of hepatitis C therapy in liver transplant‐eligible patients: Cost‐effectiveness analysis of new opportunities , 2018, Journal of viral hepatitis.

[10]  J. Pawlotsky,et al.  A novel standardized deep sequencing-based assay for hepatitis C virus genotype determination , 2018, Scientific Reports.

[11]  P. Read,et al.  Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. , 2018, The lancet. Gastroenterology & hepatology.

[12]  J. Chhatwal,et al.  Should we treat acute hepatitis C? A decision and cost‐effectiveness analysis , 2018, Hepatology.

[13]  M. Manns,et al.  Interferon‐free therapy of chronic hepatitis C with direct‐acting antivirals does not change the short‐term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis , 2018, Alimentary pharmacology & therapeutics.

[14]  Chih-Wei Lin,et al.  Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure , 2018, Hepatology.

[15]  T. Asselah,et al.  Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection , 2018, The New England journal of medicine.

[16]  R. Talwani,et al.  The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection , 2018, Journal of Gastroenterology.

[17]  D. Holtzman,et al.  Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014 , 2018, American journal of public health.

[18]  Ding‐Shinn Chen,et al.  Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  T. Hassanein,et al.  Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial , 2018, Hepatology.

[20]  A. Federico,et al.  Efficacy and safety of new direct antiviral agents in hepatitis C virus–infected patients with diffuse large B‐cell non‐Hodgkin's lymphoma , 2018, Hepatology.

[21]  G. Dore,et al.  Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. , 2017, Journal of hepatology.

[22]  X. Forns,et al.  Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. , 2017, Journal of hepatology.

[23]  M. Cappellini,et al.  Treatment of hepatitis C virus infection with direct‐acting antiviral drugs is safe and effective in patients with hemoglobinopathies , 2017, American journal of hematology.

[24]  K. Chayama,et al.  Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection , 2017, Hepatology.

[25]  Pei-Jer Chen,et al.  Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. , 2017, Gastroenterology.

[26]  P. Hayes,et al.  The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen. , 2017, Journal of hepatology.

[27]  Ioan Sporea,et al.  Assessment of biopsy‐proven liver fibrosis by two‐dimensional shear wave elastography: An individual patient data‐based meta‐analysis , 2017, Hepatology.

[28]  M. Buti,et al.  Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. , 2017, Gastroenterology.

[29]  C. Niederau,et al.  Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. , 2017, Journal of hepatology.

[30]  D. Dieterich,et al.  Real‐world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta‐analysis , 2017, Journal of viral hepatitis.

[31]  J. Leung,et al.  Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review , 2017, The Lancet. Global health.

[32]  J. Leung,et al.  Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review , 2017, The Lancet. Global health.

[33]  S. Pol,et al.  Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment , 2017, The New England journal of medicine.

[34]  M. Berenguer,et al.  Liver Volume as a Predictor of Functional Improvement Post-DAA Treatment , 2017, Transplantation.

[35]  T. Hassanein,et al.  Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. , 2017, The Lancet. Infectious diseases.

[36]  P. Rosenthal,et al.  Sofosbuvir and ribavirin in adolescents 12‐17 years old with hepatitis C virus genotype 2 or 3 infection , 2017, Hepatology.

[37]  G. di Perri,et al.  Treatment with direct‐acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study , 2017, Journal of viral hepatitis.

[38]  K. Reddy,et al.  Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study , 2017, Hepatology.

[39]  V. de Lédinghen,et al.  Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[40]  D. Goldberg,et al.  Transplanting HCV-Infected Kidneys into Uninfected Recipients. , 2017, The New England journal of medicine.

[41]  H. Hagan,et al.  Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs , 2017, The Cochrane database of systematic reviews.

[42]  C. Cunningham,et al.  High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic. , 2017, The International journal on drug policy.

[43]  C. Gilks,et al.  Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network. , 2017, The International journal on drug policy.

[44]  P. Read,et al.  Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. , 2017, The International journal on drug policy.

[45]  Chien-Jen Chen,et al.  Hepatitis C viral load, genotype, and increased risk of developing end‐stage renal disease: REVEAL‐HCV study , 2017, Hepatology.

[46]  S. Sockalingam,et al.  Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. , 2017, The International journal on drug policy.

[47]  William M. Lee,et al.  Elbasvir/Grazoprevir for Patients With Hepatitis C Virus Infection and Inherited Blood Disorders: A Phase III Study , 2017, Hepatology.

[48]  G. Cabibbo,et al.  Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct‐acting antivirals? A prospective multicentre study , 2017, Alimentary pharmacology & therapeutics.

[49]  T. Hassanein,et al.  Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. , 2017, Journal of hepatology.

[50]  Z. Younossi.  Hepatitis C Infection: A Systemic Disease , 2017, Clinics in liver disease.

[51]  S. Pol,et al.  Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. , 2017, The lancet. Gastroenterology & hepatology.

[52]  M. Kowgier,et al.  Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia , 2017, The American Journal of Gastroenterology.

[53]  C. Combet,et al.  Direct‐acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[54]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[55]  Brian L. Pearlman,et al.  Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. , 2017, Gastroenterology.

[56]  E. Daar,et al.  Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[57]  T. Asselah,et al.  Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. , 2017, The lancet. Gastroenterology & hepatology.

[58]  G. Dore,et al.  Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study. , 2017, The lancet. Gastroenterology & hepatology.

[59]  G. Ioannou,et al.  Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. , 2017, Journal of hepatology.

[60]  L. Kamal,et al.  Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients With Directly Acting Antiviral Agents , 2017, Transplantation.

[61]  S. Pol,et al.  Efficacy and Safety of Sofosbuvir Plus Daclatasvir for Treatment of HCV-Associated Cryoglobulinemia Vasculitis. , 2017, Gastroenterology.

[62]  J. Kramer,et al.  The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection , 2017, Gut.

[63]  P. Rosenthal,et al.  The safety and effectiveness of ledipasvir−sofosbuvir in adolescents 12‐17 years old with hepatitis C virus genotype 1 infection , 2017, Hepatology.

[64]  D. Klatzmann,et al.  Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis. , 2017, Gastroenterology.

[65]  M. Buti,et al.  Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end‐stage liver disease: Analysis of data from the Hepa‐C registry , 2017, Hepatology.

[66]  M. Manns,et al.  Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection , 2017, The New England journal of medicine.

[67]  Monica Monti,et al.  Virological and Clinical Response to Interferon-Free Regimens in Patients with HCV-Related Mixed Cryoglobulinemia: Preliminary Results of a Prospective Pilot Study. , 2017, Current drug targets.

[68]  J. Rockstroh,et al.  Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial. , 2017, The lancet. Gastroenterology & hepatology.

[69]  G. Gerken,et al.  Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients , 2017, Transplantation.

[70]  T. Schiano,et al.  Ledipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus , 2017, Clinical transplantation.

[71]  M. Manns,et al.  Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.

[72]  R. Bhattacharya,et al.  Sofosbuvir‐based regimens for the treatment of chronic hepatitis C in severe renal dysfunction , 2017, Hepatology communications.

[73]  M. Hughes,et al.  Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1–Infected Individuals: SWIFT-C , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[74]  I. Song,et al.  Impact of antiviral therapy on hepatocellular carcinoma and mortality in patients with chronic hepatitis C: systematic review and meta-analysis , 2017, BMC Gastroenterology.

[75]  X. Forns,et al.  Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. , 2017, Journal of hepatology.

[76]  X. Forns,et al.  Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus–Associated Cryoglobulinemia Treated With Direct‐Acting Antivirals , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[77]  K. Kowdley,et al.  Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection , 2017, Hepatology.

[78]  T. Ayer,et al.  Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list , 2017, Hepatology.

[79]  Gamal Esmat,et al.  Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.

[80]  M. Saag,et al.  TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir , 2017, The Journal of infectious diseases.

[81]  L. Kucirka,et al.  Changes in Utilization and Discard of Hepatitis C–Infected Donor Livers in the Recent Era , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[82]  P. Cacoub,et al.  Hepatitis C Virus Infection and Rheumatic Diseases: The Impact of Direct-Acting Antiviral Agents. , 2017, Rheumatic diseases clinics of North America.

[83]  M. Manns,et al.  Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. , 2017, The Lancet. Infectious diseases.

[84]  L. Qian,et al.  Acoustic Radiation Force Impulse (ARFI) Elastography for non‑invasive evaluation of hepatic fibrosis in chronic hepatitis B and C patients: a systematic review and meta-analysis. , 2017, Medical ultrasonography.

[85]  A. Gasbarrini,et al.  Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon , 2017, Alimentary pharmacology & therapeutics.

[86]  G. Dore,et al.  Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[87]  K. Koike,et al.  The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. , 2016, Journal of hepatology.

[88]  A. Mangia,et al.  Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[89]  E. Williams,et al.  Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. , 2016, Drug and alcohol dependence.

[90]  A. Lok,et al.  Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. , 2016, Gastroenterology.

[91]  T. Vos,et al.  Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. , 2016, The Lancet. Infectious diseases.

[92]  R. Bruno,et al.  Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. , 2016, Blood.

[93]  M. Manns,et al.  Treatment With LedipasvirSofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection , 2016, Annals of Internal Medicine.

[94]  J. W. Haukeland,et al.  Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study , 2016, PloS one.

[95]  A. Aghemo,et al.  Sofosbuvir‐based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[96]  T. Ayer,et al.  Hepatitis C Disease Burden in the United States in the era of oral direct‐acting antivirals , 2016, Hepatology.

[97]  J. Pawlotsky.  The end of the hepatitis C burden: Really? , 2016, Hepatology.

[98]  Marco Silva,et al.  High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. , 2016, Journal of hepatology.

[99]  R. Stauber,et al.  Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. , 2016, Journal of hepatology.

[100]  T. Asselah,et al.  Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection , 2016, Hepatology.

[101]  J. Macías,et al.  HCV epidemiology in high-risk groups and the risk of reinfection. , 2016, Journal of hepatology.

[102]  J. Vauthey,et al.  Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment. , 2016, Journal of hepatology.

[103]  A. J. van der Meer,et al.  Reversion of disease manifestations after HCV eradication. , 2016, Journal of hepatology.

[104]  S. Pol,et al.  Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study. , 2016, Annals of the rheumatic diseases.

[105]  G. Cabibbo,et al.  Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing. , 2016, Journal of hepatology.

[106]  J. Bruix,et al.  Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. , 2016, Journal of hepatology.

[107]  A. Walker,et al.  Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. , 2016, Journal of hepatology.

[108]  G. Gores,et al.  Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. , 2016, Journal of hepatology.

[109]  L. Bolondi,et al.  Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. , 2016, Journal of hepatology.

[110]  M. Manns,et al.  Ledipasvir/Sofosbuvir plus Ribavirin (LDV/SOF+RBV) for 12 Weeks in Decompensated HCV Genotype 1 Patients: SOLAR-1 and-2 Studies Compared to a Real-World Dataset , 2016 .

[111]  Kathy Petoumenos,et al.  Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE‐C II study , 2016, Hepatology.

[112]  A. Aghemo,et al.  Quantification of Core Antigen Monitors Efficacy of Direct-acting Antiviral Agents in Patients With Chronic Hepatitis C Virus Infection. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[113]  R. Stauber,et al.  DAA‐based antiviral treatment of patients with chronic hepatitis C in the pre‐ and postkidney transplantation setting , 2016, Transplant international : official journal of the European Society for Organ Transplantation.

[114]  R. Facchetti,et al.  Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. , 2016, Journal of hepatology.

[115]  D. Nickle,et al.  Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. , 2016, Annals of internal medicine.

[116]  H. Innes,et al.  Factors associated with spontaneous clearance of chronic hepatitis C virus infection. , 2016, Journal of hepatology.

[117]  Anna E. Rutherford,et al.  Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection , 2016, PloS one.

[118]  Jean-Michel Pawlotsky,et al.  Hepatitis C Virus Resistance to Direct-Acting Antiviral Drugs in Interferon-Free Regimens. , 2016, Gastroenterology.

[119]  Y. Yazdanpanah,et al.  Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. , 2016, Journal of hepatology.

[120]  J. M. Freiman,et al.  Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection , 2016, Annals of Internal Medicine.

[121]  A. Hill,et al.  The use of generic medications for hepatitis C , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[122]  S. Pol.  Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. , 2016, Journal of hepatology.

[123]  A. Walker,et al.  Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. , 2016, Journal of hepatology.

[124]  M. Manns,et al.  Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. , 2016, The Lancet. Infectious diseases.

[125]  K. Reddy,et al.  Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease. , 2016, Gastroenterology.

[126]  P. Maisonneuve,et al.  Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. , 2016, Journal of hepatology.

[127]  N. Terrault,et al.  Safety and efficacy of sofosbuvir‐containing regimens in hepatitis C‐infected patients with impaired renal function , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[128]  J. Pawlotsky,et al.  Performance of rapid diagnostic tests for the detection of antibodies to hepatitis C virus in whole blood collected on dried blood spots , 2016, Journal of viral hepatitis.

[129]  Z. Konopski,et al.  Hepatitis C reinfection after sustained virological response. , 2016, Journal of hepatology.

[130]  J. Pawlotsky,et al.  Prospective assessment of rapid diagnostic tests for the detection of antibodies to hepatitis C virus, a tool for improving access to care. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[131]  L. Rostaing,et al.  Efficacy and Safety of Sofosbuvir‐Based Antiviral Therapy to Treat Hepatitis C Virus Infection After Kidney Transplantation , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[132]  J. Pawlotsky,et al.  Clinical Utility of HCV Core Antigen Detection and Quantification in the Diagnosis and Management of Patients with Chronic Hepatitis C Receiving an All-Oral, Interferon-Free Regimen , 2016, Antiviral therapy.

[133]  T. Asselah,et al.  Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. , 2016, The Lancet. Infectious diseases.

[134]  J. Pawlotsky,et al.  Dried Blood Spots: A Tool to Ensure Broad Access to Hepatitis C Screening, Diagnosis, and Treatment Monitoring. , 2016, The Journal of infectious diseases.

[135]  E. Schiff,et al.  Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence , 2016, Hepatology.

[136]  B. Maille,et al.  Severe Pulmonary Arterial Hypertension in Patients Treated for Hepatitis C With Sofosbuvir. , 2016, Chest.

[137]  R. Chung,et al.  Treatment of hepatitis C virus–associated mixed cryoglobulinemia with direct‐acting antiviral agents , 2016, Hepatology.

[138]  D. Bernstein,et al.  Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. , 2016, Journal of hepatology.

[139]  R. Riley,et al.  Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[140]  T. Asselah,et al.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. , 2015, The New England journal of medicine.

[141]  K. Reddy,et al.  Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. , 2015, The New England journal of medicine.

[142]  T. Berg,et al.  Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. , 2015, The New England journal of medicine.

[143]  J. Pawlotsky,et al.  Virologic Tools for HCV Drug Resistance Testing , 2015, Viruses.

[144]  C. Stedman,et al.  Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. , 2015, Gastroenterology.

[145]  M. Manns,et al.  Extrahepatic morbidity and mortality of chronic hepatitis C. , 2015, Gastroenterology.

[146]  J. Ward,et al.  Cost‐effectiveness of strategies for testing current hepatitis C virus infection , 2015, Hepatology.

[147]  T. Hassanein,et al.  Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study , 2015, The Lancet.

[148]  Hemant A Shah,et al.  Lymphoma Remission by Interferon-Free HCV Eradication Without Chemotherapy , 2015, ACG case reports journal.

[149]  D. De Angelis,et al.  Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs. , 2015, The International journal on drug policy.

[150]  M. Polis,et al.  Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. , 2015, The Lancet. Infectious diseases.

[151]  E. Schiff,et al.  Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. , 2015, Gastroenterology.

[152]  P. Sax,et al.  Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. , 2015, The New England journal of medicine.

[153]  C. Katlama,et al.  Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. , 2015, The lancet. HIV.

[154]  M. King,et al.  Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. , 2015, Journal of hepatology.

[155]  P. Marcellin,et al.  Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis , 2015, Hepatology.

[156]  Asociacion Latinoamericana para el Estudio del Higado.  EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. , 2015, Journal of hepatology.

[157]  M. Kretzschmar,et al.  Hepatitis C virus treatment as prevention among injecting drug users: who should we cure first? , 2015, Addiction.

[158]  K. Reddy,et al.  GrazoprevirElbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection , 2015, Annals of Internal Medicine.

[159]  S. Pol,et al.  Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. , 2015, Blood.

[160]  Lee-Jen Wei,et al.  Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[161]  Jason Grebely,et al.  Mixed HCV infection and reinfection in people who inject drugs—impact on therapy , 2015, Nature Reviews Gastroenterology &Hepatology.

[162]  M. Rizzetto,et al.  Chronic hepatitis C virus infection and lymphoproliferative disorders: Mixed cryoglobulinemia syndrome, monoclonal gammopathy of undetermined significance, and B‐cell non‐Hodgkin lymphoma , 2015, Journal of gastroenterology and hepatology.

[163]  M. Khuroo,et al.  Diagnostic Accuracy of Point-of-Care Tests for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis , 2015, PloS one.

[164]  S. Ahn,et al.  Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin , 2015, Digestive Diseases and Sciences.

[165]  P. Pattison,et al.  The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs , 2014, Hepatology.

[166]  M. Bellis,et al.  Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis , 2014, The Lancet.

[167]  J. Dufour,et al.  Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. , 2014, JAMA.

[168]  F. Lehner,et al.  Hepatitis C virus core antigen testing in liver and kidney transplant recipients , 2014, Journal of viral hepatitis.

[169]  M. Alavi,et al.  Continued low uptake of treatment for hepatitis C virus infection in a large community‐based cohort of inner city residents , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[170]  J. Pawlotsky,et al.  Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[171]  O. Weiland,et al.  ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. , 2014, Gastroenterology.

[172]  J. Lazarus,et al.  Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention , 2014, PloS one.

[173]  R. Marinho,et al.  ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. , 2014, The New England journal of medicine.

[174]  Stefan Zeuzem,et al.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[175]  Robert Herring,et al.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.

[176]  Sanjeev Arora,et al.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. , 2014, The New England journal of medicine.

[177]  M. Abrahamowicz,et al.  Sustained drug use changes after hepatitis C screening and counseling among recently infected persons who inject drugs: a longitudinal study. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[178]  X. Forns,et al.  Interferon-Free Regimens in the Liver-Transplant Setting , 2014, Seminars in Liver Disease.

[179]  A. Lok,et al.  Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. , 2014, The New England journal of medicine.

[180]  Brian L. Pearlman,et al.  svr results of a once-daily regimen of simeprevir (tmc435) plus sofosbuvir (gs-7977) with or without ribavirin in cirrhotic and non-cirrhotic Hcv genotype 1 treatment-naïve and prior null responder patients: The Cosmos study : lb-3 , 2013 .

[181]  D. Brainard,et al.  sofosbuvir in Combination With Pegifn and Ribavirin for 12 Weeks Provides High Svr Rates in Hcv-infected Genotype 2 or 3 Treatment Experienced Patients with and without Compensated Cirrhosis: Results from the Lonestar-2 Study : lb-4 , 2013 .

[182]  P. Rosenthal,et al.  Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: A retrospective study , 2013, Hepatology.

[183]  T. Eley,et al.  Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir , 2013, Hepatology.

[184]  D. Hazuda,et al.  Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. , 2013, Virology.

[185]  Brad J. Wood,et al.  Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. , 2013, JAMA.

[186]  M. Hellard,et al.  Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals , 2013, Hepatology.

[187]  M. Hellard,et al.  Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[188]  P. Bruggmann,et al.  Models of care for the management of hepatitis C virus among people who inject drugs: one size does not fit all. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[189]  P. Vickerman,et al.  Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution Therapy , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[190]  J. Hahn,et al.  Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[191]  B. Grady,et al.  Hepatitis C virus reinfection following treatment among people who use drugs. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[192]  Tara L. Kieffer,et al.  Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[193]  Elie A Akl,et al.  GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. , 2013, Journal of clinical epidemiology.

[194]  Roger Chou,et al.  Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection , 2013, Annals of Internal Medicine.

[195]  F. Danjou,et al.  Natural history of hepatitis C in thalassemia major: a long‐term prospective study , 2013, European journal of haematology.

[196]  R. Fontana,et al.  Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[197]  M. Manns,et al.  Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. , 2013, The Lancet. Infectious diseases.

[198]  E. Schiff,et al.  Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. , 2013, The New England journal of medicine.

[199]  John McNally,et al.  Sofosbuvir for previously untreated chronic hepatitis C infection. , 2013, The New England journal of medicine.

[200]  G. Dore,et al.  Sa2072 Simeprevir (TMC435) With Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Nai;auve Patients: Results From QUEST-1, a Phase III Trial , 2013 .

[201]  M. Manns,et al.  869a Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype-1 Infection in Treatment-Naive Patients: Results From QUEST-2, a Phase III Trial , 2013 .

[202]  K. Reddy,et al.  Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. , 2013, The Lancet. Infectious diseases.

[203]  X. Forns,et al.  869b Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients Who Relapsed After Previous Interferon-Based Therapy: Results From PROMISE, a Phase III Trial , 2013 .

[204]  G. Dore,et al.  PostersLate-Breaker Poster Abstracts1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL , 2013 .

[205]  M. Manns,et al.  1413 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL , 2013 .

[206]  D. Nelson,et al.  845 ONCE DAILY SOFOSBUVIR PLUS RIBAVIRIN FOR 12 AND 24 WEEKS IN TREATMENT-NAÏVE PATIENTS WITH HCV INFECTION: THE QUANTUM STUDY , 2013 .

[207]  Bryce D. Smith,et al.  Eradication of Hepatitis C Virus Infection and the Development of Hepatocellular Carcinoma , 2013, Annals of Internal Medicine.

[208]  M. Manns,et al.  Anemia during treatment with peginterferon Alfa‐2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT‐2) trial , 2013, Hepatology.

[209]  Yoshiyuki Suzuki,et al.  Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C , 2013, Hepatology.

[210]  M. Gao,et al.  Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir , 2013, Antimicrobial Agents and Chemotherapy.

[211]  C. Stedman,et al.  Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. , 2013, The New England journal of medicine.

[212]  M. Manns,et al.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. , 2012, JAMA.

[213]  Rosanna Peeling,et al.  Accuracy of Rapid and Point-of-Care Screening Tests for Hepatitis C , 2012, Annals of Internal Medicine.

[214]  S. Kamili,et al.  Laboratory diagnostics for hepatitis C virus infection. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[215]  Jeffrey A. Alexander,et al.  Patient-physician role relationships and patient activation among individuals with chronic illness. , 2012, Health services research.

[216]  J. Kaldor,et al.  Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection , 2012, Hepatology.

[217]  P. Brissot,et al.  A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse. , 2012, Journal of hepatology.

[218]  S. Alavian,et al.  Education by a nurse increases the adherence to therapy in chronic hepatitis C patients. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[219]  P. Vickerman,et al.  Cost‐effectiveness of hepatitis C virus antiviral treatment for injection drug user populations , 2012, Hepatology.

[220]  G. Dore,et al.  What Is Killing People with Hepatitis C Virus Infection? , 2011, Seminars in liver disease.

[221]  Louisa Degenhardt,et al.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews , 2011, The Lancet.

[222]  Geoffrey Dusheiko,et al.  Telaprevir for previously untreated chronic hepatitis C virus infection. , 2011, The New England journal of medicine.

[223]  O. Weiland,et al.  Telaprevir for retreatment of HCV infection. , 2011, The New England journal of medicine.

[224]  P. Vickerman,et al.  Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. , 2011, Journal of hepatology.

[225]  Lai Wei,et al.  [Introduction and comments on EASL clinical practice guidelines: management of hepatitis C virus infection]. , 2011, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[226]  Stefan Zeuzem,et al.  Boceprevir for previously treated chronic HCV genotype 1 infection. , 2011, The New England journal of medicine.

[227]  Sprint Investigators,et al.  Boceprevir for Untreated Chronic HCV Genotype 1 Infection , 2011 .

[228]  V. Garg,et al.  1244 THE PHARMACOKINETIC INTERACTION BETWEEN METHADONE AND THE INVESTIGATIONAL HCV PROTEASE INHIBITOR TELAPREVIR , 2011 .

[229]  D. Lavanchy,et al.  Evolving epidemiology of hepatitis C virus. , 2011, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[230]  J. Raffa,et al.  Impact of hepatitis C virus infection on all‐cause and liver‐related mortality in a large community‐based cohort of inner city residents , 2011, Journal of viral hepatitis.

[231]  D. Scott,et al.  Adverse Impact of Hepatitis C Virus Infection on Renal Replacement Therapy and Renal Transplant Patients in Australia and New Zealand , 2010, Transplantation.

[232]  P. Bedossa,et al.  Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). , 2010, Journal of hepatology.

[233]  D. Dieterich,et al.  A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. , 2010, Gastroenterology.

[234]  Jennifer L. Rodis,et al.  Evaluation of Medication Adherence and Quality of Life in Patients With Hepatitis C Virus Receiving Combination Therapy , 2010, Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates.

[235]  M. Chevallier,et al.  Non‐invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[236]  B. Conway,et al.  Reinfection with hepatitis C virus following sustained virological response in injection drug users , 2009, Journal of gastroenterology and hepatology.

[237]  P. Bruggmann,et al.  Treatment outcome in relation to alcohol consumption during hepatitis C therapy: an analysis of the Swiss Hepatitis C Cohort Study. , 2010, Drug and alcohol dependence.

[238]  G. Colucci,et al.  Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. , 2010, Journal of hepatology.

[239]  T. Asselah,et al.  Twelve weeks posttreatment follow‐up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin , 2010, Hepatology.

[240]  P. Marcellin,et al.  The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[241]  M. Volk,et al.  A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[242]  V. de Lédinghen,et al.  Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. , 2010, Journal of hepatology.

[243]  J. Pawlotsky,et al.  Hepatitis C Virus (HCV) Genotype 1 Subtype Identification in New HCV Drug Development and Future Clinical Practice , 2009, PloS one.

[244]  T. Berg,et al.  Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin , 2009, Scandinavian journal of gastroenterology.

[245]  E. Wang,et al.  Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation. , 2009, Journal of hepatology.

[246]  M. Picot,et al.  Dried blood spot for hepatitis C virus serology and molecular testing , 2009, Hepatology.

[247]  P. Colombani,et al.  Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. , 2009, Journal of pediatric gastroenterology and nutrition.

[248]  J. Wands,et al.  Hepatitis C Virus and Alcohol , 2009, Seminars in liver disease.

[249]  J. Pawlotsky,et al.  Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes. , 2008, Best practice & research. Clinical gastroenterology.

[250]  D. D. Des Jarlais,et al.  Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. , 2008, American journal of epidemiology.

[251]  T. Santantonio,et al.  Acute hepatitis C: current status and remaining challenges. , 2008, Journal of hepatology.

[252]  B. Gärtner,et al.  Differences between Two Real-Time PCR-Based Hepatitis C Virus (HCV) Assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and One Signal Amplification Assay (Versant HCV RNA 3.0) for RNA Detection and Quantification , 2008, Journal of Clinical Microbiology.

[253]  S. Currie,et al.  Corrigendum to “A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus” [Drug Alcohol Depend. 93(1–2) (2008) 148–154] , 2008 .

[254]  S. Kamal.  Acute Hepatitis C: A Systematic Review , 2008, The American Journal of Gastroenterology.

[255]  M. Berenguer,et al.  Clinical Benefits of Antiviral Therapy in Patients with Recurrent Hepatitis C Following Liver Transplantation , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[256]  S. Currie,et al.  A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. , 2008, Drug and alcohol dependence.

[257]  R. Stravitz,et al.  Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha , 2007, Hepatology.

[258]  J. Pawlotsky,et al.  Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real‐time polymerase chain reaction–based method , 2007, Hepatology.

[259]  J. Ticehurst,et al.  Factors Affecting Serum Concentrations of Hepatitis C Virus (HCV) RNA in HCV Genotype 1-Infected Patients with Chronic Hepatitis , 2007, Journal of Clinical Microbiology.

[260]  M. De Luca,et al.  Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. , 2007, Journal of hepatology.

[261]  Johan Duflou,et al.  Comparative cardiac pathology among deaths due to cocaine toxicity, opioid toxicity and non-drug-related causes. , 2006, Addiction.

[262]  B. Bell,et al.  The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.

[263]  C. Trautwein,et al.  Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). , 2006, Journal of hepatology.

[264]  E. Bini,et al.  Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. , 2006, Gastroenterology.

[265]  X. Forns,et al.  Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation , 2006, Hepatology.

[266]  M. Kew.  Interaction between hepatitis B and C viruses in hepatocellular carcinogenesis , 2006, Journal of viral hepatitis.

[267]  J. Kaldor,et al.  Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies , 2006, Journal of viral hepatitis.

[268]  J. Pawlotsky,et al.  Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy , 2005, Journal of viral hepatitis.

[269]  Colin W Shepard,et al.  Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.

[270]  O. Dalgard.  Follow-up studies of treatment for hepatitis C virus infection among injection drug users. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[271]  M. Mondelli,et al.  Acute Hepatitis C: Diagnosis and Management , 2007 .

[272]  V. de Lédinghen,et al.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.

[273]  E. Schiff,et al.  Epoetin alfa improves quality of life in anemic HCV‐infected patients receiving combination therapy , 2004, Hepatology.

[274]  B. Edlin,et al.  Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[275]  U. Neumann,et al.  Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. , 2004, Journal of hepatology.

[276]  M. Manns,et al.  Long‐term follow‐up after successful interferon therapy of acute hepatitis C , 2004, Hepatology.

[277]  E. Schiff,et al.  Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. , 2004, Gastroenterology.

[278]  S. Rai,et al.  The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort. , 2004, Blood.

[279]  L. Seeff,et al.  Aasld Practice Guideline Diagnosis, Management, and Treatment of Hepatitis C , 2003 .

[280]  P. Marcellin,et al.  Peginterferon-2a and Ribavirin Combination Therapy in Chronic Hepatitis C , 2004, Annals of Internal Medicine.

[281]  G. Wu,et al.  Extrahepatic manifestations of chronic hepatitis C , 2003 .

[282]  N. Gruener,et al.  Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. , 2003, Gastroenterology.

[283]  E. Penner,et al.  Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load , 2003, Hepatology.

[284]  J. Hoofnagle,et al.  Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C , 2002, Hepatology.

[285]  M. Fried,et al.  Side effects of therapy of hepatitis C and their management , 2002, Hepatology.

[286]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[287]  E. Gane,et al.  Management of chronic viral hepatitis before and after renal transplantation , 2002, Transplantation.

[288]  J. Berlin,et al.  The association between hepatitis C infection and survival after orthotopic liver transplantation. , 2002, Gastroenterology.

[289]  X. Forns,et al.  Hepatitis C virus kinetics during and immediately after liver transplantation , 2002, Hepatology.

[290]  T. Poynard,et al.  Interferon for acute hepatitis C. , 2001, The Cochrane database of systematic reviews.

[291]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[292]  M. Manns,et al.  Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C , 2000, Nature Medicine.

[293]  L. Ferrell,et al.  HCV-related fibrosis progression following liver transplantation: increase in recent years. , 2000, Journal of hepatology.

[294]  J. Piette,et al.  Extrahepatic manifestations of chronic hepatitis C , 1999, Arthritis & Rheumatism.

[295]  J. Córdoba,et al.  High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes , 1999, Hepatology.

[296]  F. Martinez,et al.  International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[297]  A. Craxì,et al.  Interferon as treatment for acute hepatitis C , 1996, Digestive Diseases and Sciences.

[298]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[299]  J. Ward,et al.  Scaling‐up HCV prevention and treatment interventions in rural United States—model projections for tackling an increasing epidemic , 2018, Addiction.

[300]  M. Ziol,et al.  Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications. , 2017, Gastroenterology.

[301]  P. Angus,et al.  MAGELLAN-2: safety and efficacy of glecaprevir/pibrentasvir in liver or renal transplant adults with chronic hepatitis C genotype 1–6 infection , 2017 .

[302]  J. Chen,et al.  Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct‐acting Antiviral Agents , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[303]  G. Ioannou,et al.  Reply to: "Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything" and "More extended indication of DAA therapy in patients with HCC, affordability, and further statistical considerations". , 2017, Journal of hepatology.

[304]  K. Agarwal,et al.  Direct-acting antiviral therapy in patients with hepatocellular cancer: The timing of treatment is everything. , 2017, Journal of hepatology.

[305]  S. Okolicsanyi,et al.  Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? , 2017, Journal of hepatology.

[306]  N. Luhmann,et al.  Effectiveness of DAA-based treatment of HCV in active people who inject drugs living in middle income countries (MIC): the results of a prospective cohort study in Tbilisi, Georgia , 2017 .

[307]  M. Buti,et al.  Sustained viral response following treatment with direct acting antiviral agents for chronic hepatitis C and the risk of hepatocellular carcinoma , 2017 .

[308]  M. Manns,et al.  Real world effectiveness of 8 vs 12 weeks of ledipasvir/sofosbuvir (LDV/SOF) in blacks with HCV: A comparative analysis of clinical trials with real world cohorts. , 2017 .

[309]  E. Gane,et al.  Safety and efficacy of treatment with once-daily ledipasvir/sofosbuvir (90/400 mg) for 12 weeks in genotype 1 hcv-infected patients with severe renal impairment. , 2017 .

[310]  R. Chung,et al.  SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy , 2017 .

[311]  T. Asselah,et al.  ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis , 2017 .

[312]  T. Pilot‐Matias,et al.  Pooled resistance analysis in HCV genotype 1–6-infected patients treated with glecaprevir/pibrentasvir in phase 2 and 3 clinical trials , 2017 .

[313]  M. Heo,et al.  The PREVAIL Study: intensive models of HCV care for people who inject drugs , 2017 .

[314]  M. Kurosaki,et al.  Direct acting antivirals did not increase early recurrences after curative treatment of HCV related hepatocellular carcinoma in comparison with IFN-based treatment , 2017 .

[315]  S. Katz,et al.  Randomized controlled trial of cash incentives or peer mentors to improve HCV linkage and treatment among HIV/HCV coinfected persons who inject drugs: the CHAMPS Study , 2017 .

[316]  F. Marra,et al.  Partial directly observed therapy with ombitasvir/paritaprevir based regimens allows for successful treatment of patients on daily supervised methadone , 2017 .

[317]  S. Pol,et al.  Safety and efficacy of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection genotype 1–6 and chronic kidney disease: an integrated analysis , 2017 .

[318]  P. Read,et al.  Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: the SIMPLIFY study , 2017 .

[319]  R. Facchetti,et al.  Delisting of liver transplant candidates with chronic hepatitis C virus infection after viral eradication: outcome after delisting: a European study , 2017 .

[320]  A. Chokkalingam,et al.  No increased risk of hepatocellular carcinoma recurrence in patients following interferon-free, direct acting anti-viral treatment for hepatitis C virus: a cohort study using large-scale administrative medical claims data , 2017 .

[321]  R. Talwani,et al.  Efficacy and safety of elbasvir/grazoprevir in treatment-naïve patients with chronic HCV GT 1, GT 4 and GT 6 infection (C-CORAL): a phase III randomized multinational clinical trial , 2017 .

[322]  O. Weiland,et al.  Safety of glecaprevir/pibrentasvir in adults with chronic genotype 1–6 hepatitis C virus infection: an integrated analysis , 2017 .

[323]  B. Bacon,et al.  Utilization of DAA therapies ledipasvir/sofosbuvir and sofosbuvir/ velpatasvir in patients with genotype 1 HCV: real-world experience from the TRIO Network , 2017 .

[324]  Brian L. Pearlman,et al.  Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. , 2017, Gastroenterology.

[325]  C. Cooper,et al.  Safety and efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials , 2017 .

[326]  D. Goldberg,et al.  Transplanting HCV-Infected Kidneys into Uninfected Recipients. , 2017, The New England journal of medicine.

[327]  J. Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2016. , 2017, Journal of hepatology.

[328]  N. Terrault,et al.  Direct-acting antivirals for hepatitis C do not increase the risk of hepatocellular carcinoma recurrence after locoregional therapy or liver transplant waitlist dropout , 2017 .

[329]  B. Conway,et al.  Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials. , 2016, Journal of hepatology.

[330]  U. Spengler,et al.  Retreatment of Patients who Failed Daa-Combination Therapies: Real-World Experience from a Large Hepatitis C Resistance Database , 2016 .

[331]  H. Stellbrink,et al.  HCV Reinfection Incidence and Outcomes among HIV Infected MSM in Western Europe , 2016 .

[332]  F. Marra,et al.  Introduction of Directly Observed Community Pharmacy Dispensing of Directing Acting Antivirals Achieves High Sustained Viral Response Rates in a Difficult to Treat Cohort , 2016 .

[333]  R. Marinho,et al.  Efficacy and Safety of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir without Ribavirin in Patients with HCV Genotype 1b with or without Compensated Cirrhosis: Pooled Analysis across 5 Clinical Trials , 2016 .

[334]  D. Samuel,et al.  Pros and Cons: Usage of organs from donors infected with hepatitis C virus - Revision in the direct-acting antiviral era. , 2016, Journal of hepatology.

[335]  J. Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2015. , 2015, Journal of hepatology.

[336]  M. Hellard,et al.  Does informing people who inject drugs of their hepatitis C status influence their injecting behaviour? Analysis of the Networks II study. , 2014, The International journal on drug policy.

[337]  S. Zeuzem,et al.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection. , 2014, Journal of hepatology.

[338]  P. Bruggmanna,et al.  Treatment outcome in relation to alcohol consumption during hepatitis C therapy : An analysis of the Swiss Hepatitis C Cohort Study , 2011 .

[339]  S. Zeuzem,et al.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection. , 2011, Journal of hepatology.

[340]  M. Kedda,et al.  The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. , 1997, Gastroenterology.